St. Joseph Mercy Hospital is a [[Roman Catholic|Catholic] hospital. It is Located on Parade Street, Kingston in Georgetown, Guyana. It was established by the members of the Sword of the Spirit movement and was officially opened in 1945. The hospital includes a School of Nursing. The oldest wing of the hospital burnt down on Monday, May 10, 2010, at 7 am. In 2020, the hospital opened a specialized COVID-19 treatment ward.
This study aimed to evaluate patient-reported outcomes, functional recovery, satisfaction, and implant survivorship for cementless and cemented TKA. A prospective, non-randomized, multicenter study was conducted on 453 patients. Cohort 1 (n = 373 knees) received a fully cementless construct with the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with Peri-Apatite, and the Triathlon Tibial Insert. Cohort 2 (n = 147 knees) received a fully cemented construct with identical implant design. Oxford Knee Score (OKS), 2011 Knee Society Score (KSS), and Short Form 12 scores were recorded preoperatively and at 6 weeks, 6 months, 1 year, and 2 years postoperatively. Implant survivorship and adverse events were also recorded. OKS (mean difference [MD] 1.5, p = 0.0123), KSS Symptoms for pain (with level walking [MD 0.62, p = 0.0007]; with stairs or incline [MD 0.85, p = 0.0037), KSS Patient satisfaction (MD 2.31, p = 0.0004), and KSS Functional Activities (MD 0.53, p = 0.0108) were significantly greater in Cohort 1 out to 2 years postoperatively. The Kaplan–Meier estimated all-cause survivorship was 98.2
IMPORTANCE This was the first study, to the authors' knowledge, to statistically evaluate the predictive accuracy of Collaborative Ocular Tuberculosis Study (COTS) calculator in guiding initiation of antitubercular therapy (ATT) in patients with clinically suspicious tubercular uveitis (TBU) in an international cohort. OBJECTIVE To evaluate the accuracy of a score of 4 or greater on the online COTS calculator in recommending ATT initiation. DESIGN, SETTING, AND PARTICIPANTS This study was an evaluation of a diagnostic test or technology. Data input required for the COTS calculator were extracted from the COTS-1 study dataset, which comprised retrospective, observational records of patients with TBU who were monitored for 12 months after treatment. Patients were recruited from international ophthalmic centers. In the absence of a traditional criterion standard, the 12-month treatment response to ATT was used to classify patients as disease positive or negative. The accuracy of clinicians at the ATT decision-making stage in the COTS-1 study was set against COTS calculator scores of 4 or greater. Diagnostic accuracy metrics, including sensitivity, specificity, positive predictive value (PPV), precision, recall, and F1 score, were computed. Data collected from January 2004 to December 2014 were analyzed. EXPOSURES COTS calculator to guide initiation of ATT in patients with TBU. MAIN OUTCOMES AND MEASURES Comparison of accuracy between clinician judgment and the COTS calculator, analyzed at varying scores and further stratified by tuberculosis endemicity. RESULTS Of the 492 participants (mean [SD] age, 42.3 [19.0] years; 233 male [47.3%]), application of the COTS calculator identified 225 (45.7%) with high or very high probability to start ATT (score = 4 or 5) and 111 (22.5%) with very high probability alone (score = 5). COTS-5 exhibited the highest specificity (88.7%; 95% CI, 81.4%-93.8%) compared with clinician judgment (29.6%; 95% CI, 21.4%-38.8%), and clinician judgment led in sensitivity (95.5%; 95% CI, 92.9%-97.4%) compared with COTS-5 (26%; 95% CI, 21.6%-30.7%). COTS-4 and COTS-5 balanced specificity (64.3%; 95% CI, 54.9%-73.1%) and sensitivity (48.8%; 95% CI, 43.7%-54%). PPV and sensitivity were consistently higher in the endemic group for all 3 tests. CONCLUSIONS AND RELEVANCE Results of this diagnostic study suggest that the COTS calculator (score >= 4) was more specific than clinician judgment for ATT initiation. Although clinician judgment is a good first step to identify all potential true positives (with high sensitivity), a second consultation with COTS-5 (with high PPV) may lead to less false positives. This tool, apt for high-prevalence, low-resource settings, recommends ATT more selectively for genuine TBU cases. Large prospective studies are essential to explore potential improvements in the calculator's sensitivity.
Abstract Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged ≥60 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-naïve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the >5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.
The prevalence of mental, emotional, and social health (MESH) challenges among youth in out-of-school time (OST) contexts is on the rise, exacerbated by the ongoing impact of the COVID-19 pandemic. In response to this escalation, recent literature has explored MESH concerns impacting youth program participants and young adult staff. This study focuses on participant and staff MESH issues within summer camps and the healthcare practices implemented by program providers to address those issues. Our four research questions are: (1) What are the characteristics of camper and staff MESH issues?; (2) What are characteristics of MESH medications managed in camps?; (3) How are camp providers preparing staff for camper MESH care?; and (4) How are camp providers responding to staff MESH care needs? Findings highlight prevalent MESH issues facing youth and young adult staff and program preparedness. Notably, our study affirmed that the most prevalent MESH issues facing youth and young adult staff are anxiety, ADHD, depression, and emotional regulation. Study findings also indicated that while many camps engage in pre-camp MESH trainings, a limited number revisit MESH topics during the summer work period. Collectively, these results offer key insights into camp providers' experiences with youth and young adult staff MESH.
Background: Patient-reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment-associated adverse events (AEs) compared with clinician-rated AEs. The authors present PROs assessing health-related quality of life (HRQoL) and treatment-related neurotoxicity for adjuvant capecitabine versus platinum on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) EA1131 trial (ClinicalTrials.gov identifier NCT02445391).Methods: Participants completed the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) and the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group neurotoxicity subscale (platinum arm only) at baseline, cycle 3 day 1 (C3D1), 6 months, and 15 months. Because of early termination, power was insufficient to test the hypothesis that HRQoL, as assessed by the NFBSI-16 treatment side-effect (TSE) subscale, would be better at 6 and 15 months in the capecitabine arm; all analyses were exploratory. Means were compared by using t-tests or the Wilcoxon rank-sum test, and proportions were compared by using the chi(2 )test.Results: Two hundred ninety-six of 330 eligible patients provided PROs. The mean NFBSI-16 TSE subscale score was lower for the platinum arm at baseline (p = .02; absolute difference, 0.6 points) and for the capecitabine arm at C3D1 (p = .04; absolute difference, 0.5 points), but it did not differ at other times. The mean change in TSE subscale scores differed between the arms from baseline to C3D1 (platinum arm, 0.15; capecitabine arm, -0.72; p = .03), but not from baseline to later time points. The mean decline in Functional Assessment of Cancer Therapy-Gynecologic Oncology Group neurotoxicity subscale scores exceeded the minimal meaningful change (1.38 points) from baseline to each subsequent time point (all p < .05).Conclusions: Despite the similar frequency of clinician-rated AEs, PROs identified greater on-treatment symptom burden with capecitabine and complemented clinician-rated AEs by characterizing patients' experiences during chemotherapy.
